SUBSCRIBE: Print / eNewsletter
Test in Development to Monitor CML Patients Halting Nilotinib Treatment
MolecularMD and Novartis are working on a diagnostic test to help determine which chronic myeloid leukemia patients may be candidates to stop taking nilotinib.
FDA Approves Ibrutinib for Chronic Lymphocytic Leukemia
The FDA has approved ibrutinib (Imbruvica) as a single-agent treatment for previously treated patients with chronic lymphocytic leukemia (CLL), under the FDA’s accelerated approval program.
Idelalisib Improves Outcomes in Leukemia and Lymphoma
The combination of idelalisib with rituximab improved survival in relapsed CLL, and idelalisib also showed antitumor activity as a single agent in patients with indolent non-Hodgkin lymphoma.
Ibrutinib CLL Trial Stopped Early
After significant improvement in progression-free survival with ibrutinib over ofatumumab, an independent data monitoring board has recommended stopping a phase III trial involving patients with relapsed or refractory CLL or SLL.